Seroatlas · Human Serome Atlas

LUZP2

Leucine zipper protein 2

Also known as: LUZP2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86TE4
Gene: LUZP2
Ensembl: ENSG00000187398
Chromosome: 11
Canonical length: 346 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Nucleoplasm,Plasma membrane,Cytosol
Secretome location: Secreted in brain

OverviewNCBI Gene

This gene encodes a leucine zipper protein. This protein is deleted in some patients with Wilms tumor-Aniridia-Genitourinary anomalies-mental Retardation (WAGR) syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011]

Canonical amino-acid sequenceUniProt

346 residues, UniProt reviewed canonical sequence.

>Q86TE4|LUZP2
     1  MKFSPAHYLL PLLPALVLST RQDYEELEKQ LKEVFKERST ILRQLTKTSR ELDGIKVNLQ
    61  SLKNDEQSAK TDVQKLLELG QKQREEMKSL QEALQNQLKE TSEKAEKHQA TINFLKTEVE
   121  RKSKMIRDLQ NENKSLKNKL LSGNKLCGIH AEESKKIQAQ LKELRYGKKD LLFKAQQLTD
   181  LEQKLAVAKN ELEKAALDRE SQMKAMKETV QLCLTSVFRD QPPPPLSLIT SNPTRMLLPP
   241  RNIASKLPDA AAKSKPQQSA SGNNESSQVE STKEGNPSTT ACDSQDEGRP CSMKHKESPP
   301  SNATAETEPI PQKLQMPPCS ECEVKKAPEK PLTSFEGMAA REEKIL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LUZP2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.59
Highest tissue expression: 17 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 17 nTPM
hypothalamus: 13 nTPM
midbrain: 12 nTPM
amygdala: 9.6 nTPM
spinal cord: 8.3 nTPM
hippocampal formation: 7.1 nTPM

Single-cell type

oligodendrocyte progenitor cells: 2,830 nCPM
other brain neurons: 593 nCPM
adrenal cortex cells: 522 nCPM
pituicytes/fscs: 431 nCPM
brain inhibitory neurons: 405 nCPM
oligodendrocytes: 389 nCPM

Immune cell

basophil: 0.2 nTPM
neutrophil: 0.1 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

midbrain: 68 nTPM
spinal cord: 39 nTPM
pons: 38 nTPM
white matter: 35 nTPM
thalamus: 34 nTPM
hypothalamus: 33 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.22
gnomAD pLI: 0
gnomAD missense Z: 0.03
DepMap mean gene effect: -0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

extracellular region

Protein domainsUniProt · Pfam · InterPro

Leucine zipper protein 2

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LUZP2 as an antibody target. Whether an autoantibody or antibody against LUZP2 could matter depends on whether native LUZP2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LUZP2 is annotated as secreted, so native LUZP2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label LUZP2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...